Key result
Ceramide-based markers, unlike LDL-C, predict 16-year CV mortality in high-risk patients.
Why the study?
LDL-C underestimates true cardiovascular risk when biased by comorbidities such as metabolic syndrome, medical treatment, and age, but whether this applies to ceramides is unclear.
Do ceramide-based markers improve the prediction of cardiovascular mortality compared to LDL-C in high-risk patients with and without metabolic syndrome?
Cohort (n=1,306)
Do ceramide-based markers improve the prediction of cardiovascular mortality compared to LDL-C in high-risk patients with and without metabolic syndrome?
Ceramide-based markers, including CERT1 and CERT2 scores, outperform LDL-C in predicting long-term cardiovascular mortality in high-risk patients regardless of metabolic syndrome status.
Ceramide markers may enhance CV mortality prediction beyond LDL-C; leaves open their integration into risk stratification pending validation.
Introduction The power of cardiovascular risk prediction is biased by comorbidities (e.g. metabolic syndrome, MetS), medical treatment, and age, which impact cholesterol levels. When applying LDL-C, the true risk of such confounded patients is often underestimated. However, it is unclear whether this likewise applies to other lipid markers, in particular ceramides. Purpose The purpose of this study was to investigate the power of ceramides for cardiovascular risk prediction. Methods In this prospective cohort study, we recorded cardiovascular mortality for 16 years in 1306 patients. Their median age was 67 years, all had a high preexisting cardiovascular risk, 53% were taking statins, and 44% had the MetS. Results Ceramide levels, CERT1 and CERT2 scores but not LDL-C differed significantly between patients with and without MetS. A Cox regression analysis adjusting for age, sex, history of smoking, hypertension, BMI and statin use revealed that LDL-C failed to predict cardiovascular mortality in patients with was well as in patients without the MetS. In contrast, ceramide-based markers were able to significantly predict cardiovascular mortality after stratification and multivariate adjustment in both subgroups. Conclusion We thus propose that ceramide-based predictors rather than LDL-C should be applied for a more accurate cardiovascular risk prediction in high risk patients with as well as in those without the MetS.
No takes yet. Share an insight, caveat, or question.
SCHNETZER et al. (2025) conducted a cohort in High preexisting cardiovascular risk (n=1,306). Ceramide-based markers (CERT1 and CERT2 scores) vs. LDL-C was evaluated on Cardiovascular mortality. Ceramide-based markers, but not LDL-C, significantly predicted cardiovascular mortality over 16 years in high-risk patients with and without metabolic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: